For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 902 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 5.11% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, VRTX has returned 9.46% so far this year. At the same time, Medical stocks have gained an average of 1.41%. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Breaking things down more, VRTX is a member of the Medical - Biomedical and Genetics industry, which includes 385 individual companies and currently sits at #81 in the Zacks Industry Rank. This group has lost an average of 1.69% so far this year, so VRTX is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to VRTX as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 902 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 5.11% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, VRTX has returned 9.46% so far this year. At the same time, Medical stocks have gained an average of 1.41%. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Breaking things down more, VRTX is a member of the Medical - Biomedical and Genetics industry, which includes 385 individual companies and currently sits at #81 in the Zacks Industry Rank. This group has lost an average of 1.69% so far this year, so VRTX is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to VRTX as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VRTX - FREE